“1. The Attorney General should as a matter of urgency cause the review of the prices of drugs purchased under the Memorandum of Understanding with a view to ensuring that drugs purchased from CIPLA Ltd are purchased at prices not higher than International prices, and drugs purchased from QCIL are not more that 15% higher than CIPLA International prices; 2. The Government of Uganda and QCIL should review the need for further importation of drugs as the QCIL plant in Uganda has already been commissioned; and 3. The Government of Uganda should consider recovery of the payments made above the 15% mark-up for drugs purchased from QCIL and payments for drugs purchased from CIPLA at prices above CIPLA International prices which amounted to USD17,826,038.94 for drugs procured between December 2009 and October 2010, and subsequent procurements which have not been calculated under this investigation” (see Amended Statement of Reference pp. 49-50). 49. It is the Applicant’s further submission that, upon receipt of a copy of the IGG report and recommendations, the Attorney General instead of implementing the latter went ahead to criticize it on various dates:Firstly, on 12th April, 2012, the Attorney General wrote to the Inspector General of Government complaining about the content of the report and specifically saying that QCIL did not take advantage of the statutory 15% local content advantage. The Attorney General added that the Whistle-blower, Mr. Godfrey Magezi, being a representative of M/S Ajanta Reference No. 5 of 2013 Page 19